The US Food and Drug Administration (FDA) has granted priority review for the biologic tezepelumab (AstraZeneca/Amgen) for treatment of severe asthma. […]
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok